Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvNeu001 injection intrastriatal transplantation for multiple system atrophy (parkinsonian type)
CTR20254863Phase 3Active
- Sponsor
- iRegene Therapeutics
- Start
- Feb 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of NOUVNEU001 in striatonigral degeneration (MSA-P), sponsored by iRegene Therapeutics. Started Feb 2026; status: active.
02
Drugs
NOUVNEU001
03
Conditions
striatonigral degeneration (MSA-P)
Beyond the preview
Go deeper on CTR20254863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254863.